Genzyme to Pay $64m to Settle Buyback Claims
Reporting that litigation between Genzyme Corporation and former shareholders involving use of "tracking stock" has settled. Genzyme will pay the plainitff class $64 million in cash subject to approval by the Court. BSF acted as lead counsel to the Class in the long running dispute.